Smith+Nephew Appoints Sybella Stanley as Non-Executive Director

Smith & Nephew Snats ( (SNN) ) has shared an update.

On January 14, 2025, Smith+Nephew announced that Sybella Stanley would join their Board as an independent Non-Executive Director starting February 1, 2025. She will also chair the Remuneration Committee from June 30, 2025, succeeding Angie Risley. Stanley brings extensive experience from her roles at RELX Plc and Tate & Lyle plc, enhancing Smith+Nephew’s board with her global business insights. This move reflects the company’s focus on strategic succession planning and strengthening governance through diverse expertise.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company specializing in the repair, regeneration, and replacement of soft and hard tissue. With a mission of ‘Life Unlimited’, the company operates in over 100 countries, employing 18,000 people across three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, the company is a constituent of the FTSE100 and generated $5.5 billion in sales in 2023.

YTD Price Performance: -1.56%

Average Trading Volume: 890,854

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $10.52B

For an in-depth examination of SNN stock, go to TipRanks’ Stock Analysis page.